Syndax Pharmaceuticals (SNDX)
(Real Time Quote from BATS)
$23.63 USD
+0.35 (1.50%)
Updated Jul 24, 2024 11:42 AM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNDX 23.63 +0.35(1.50%)
Will SNDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
Other News for SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax initiated with bullish view at Jefferies, here's why
Syndax price target raised by $2 at Stifel, here's why
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Syndax: Gearing Up For Launches